Top 5 Stocks to Buy Now
→ Do NOT Buy SpaceX – Do This Instead (From Stansberry Research) (Ad)tc pixel Free TEVA Stock Alerts

Teva Pharmaceutical Industries (TEVA) Competitors

Teva Pharmaceutical Industries logo
$33.68 -0.54 (-1.58%)
Closing price 06/25/2026 03:59 PM Eastern
Extended Trading
$33.30 -0.38 (-1.13%)
As of 08:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TEVA vs. SNY, GSK, ARGX, TAK, and RVMD

Should you buy Teva Pharmaceutical Industries stock or one of its competitors? MarketBeat compares Teva Pharmaceutical Industries with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Teva Pharmaceutical Industries include Sanofi (SNY), GSK (GSK), argenex (ARGX), Takeda Pharmaceutical (TAK), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does Teva Pharmaceutical Industries compare to Sanofi?

Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Teva Pharmaceutical Industries has a beta of 0.84, suggesting that its stock price is 16% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Comparatively, 1.0% of Sanofi shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 3.0%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.2%. Teva Pharmaceutical Industries pays out 76.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 49.2% of its earnings in the form of a dividend. Sanofi is clearly the better dividend stock, given its higher yield and lower payout ratio.

Teva Pharmaceutical Industries currently has a consensus price target of $41.78, suggesting a potential upside of 24.04%. Sanofi has a consensus price target of $51.00, suggesting a potential upside of 22.01%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Sanofi.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80
Sanofi
0 Sell rating(s)
10 Hold rating(s)
3 Buy rating(s)
2 Strong Buy rating(s)
2.47

In the previous week, Teva Pharmaceutical Industries had 8 more articles in the media than Sanofi. MarketBeat recorded 15 mentions for Teva Pharmaceutical Industries and 7 mentions for Sanofi. Teva Pharmaceutical Industries' average media sentiment score of 1.20 beat Sanofi's score of 0.63 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
11 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Sanofi
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Sanofi has higher revenue and earnings than Teva Pharmaceutical Industries. Sanofi is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.35B2.23$1.41B$1.3325.32
Sanofi$49.35B2.05$8.84B$3.5811.68

Sanofi has a net margin of 16.95% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Sanofi's return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries9.01% 43.53% 8.19%
Sanofi 16.95%13.39%7.58%

Summary

Teva Pharmaceutical Industries beats Sanofi on 11 of the 19 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to GSK?

Teva Pharmaceutical Industries (NYSE:TEVA) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

GSK has a net margin of 17.82% compared to Teva Pharmaceutical Industries' net margin of 9.01%. GSK's return on equity of 44.28% beat Teva Pharmaceutical Industries' return on equity.

Company Net Margins Return on Equity Return on Assets
Teva Pharmaceutical Industries9.01% 43.53% 8.19%
GSK 17.82%44.28%11.49%

54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 3.0%. GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.5%. Teva Pharmaceutical Industries pays out 76.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. GSK pays out 47.0% of its earnings in the form of a dividend. GSK is clearly the better dividend stock, given its higher yield and lower payout ratio.

GSK has higher revenue and earnings than Teva Pharmaceutical Industries. GSK is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Teva Pharmaceutical Industries$17.35B2.23$1.41B$1.3325.32
GSK$32.78B3.20$7.54B$3.8513.45

Teva Pharmaceutical Industries presently has a consensus target price of $41.78, suggesting a potential upside of 24.04%. GSK has a consensus target price of $53.00, suggesting a potential upside of 2.33%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, equities analysts clearly believe Teva Pharmaceutical Industries is more favorable than GSK.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Teva Pharmaceutical Industries
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80
GSK
3 Sell rating(s)
4 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Teva Pharmaceutical Industries had 11 more articles in the media than GSK. MarketBeat recorded 15 mentions for Teva Pharmaceutical Industries and 4 mentions for GSK. GSK's average media sentiment score of 1.27 beat Teva Pharmaceutical Industries' score of 1.20 indicating that GSK is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Teva Pharmaceutical Industries
11 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
GSK
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Teva Pharmaceutical Industries has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, GSK has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market.

Summary

GSK beats Teva Pharmaceutical Industries on 11 of the 18 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to argenex?

argenex (NASDAQ:ARGX) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

60.3% of argenex shares are owned by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 2.4% of argenex shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

argenex has a net margin of 31.31% compared to Teva Pharmaceutical Industries' net margin of 9.01%. argenex's return on equity of 44.37% beat Teva Pharmaceutical Industries' return on equity.

Company Net Margins Return on Equity Return on Assets
argenex31.31% 44.37% 37.55%
Teva Pharmaceutical Industries 9.01%43.53%8.19%

Teva Pharmaceutical Industries has higher revenue and earnings than argenex. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
argenex$4.66B11.86$1.29B$22.4639.57
Teva Pharmaceutical Industries$17.35B2.23$1.41B$1.3325.32

argenex has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, indicating that its stock price is 16% less volatile than the broader market.

In the previous week, Teva Pharmaceutical Industries had 4 more articles in the media than argenex. MarketBeat recorded 15 mentions for Teva Pharmaceutical Industries and 11 mentions for argenex. Teva Pharmaceutical Industries' average media sentiment score of 1.20 beat argenex's score of 0.09 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
argenex
0 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral
Teva Pharmaceutical Industries
11 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

argenex presently has a consensus price target of $1,023.39, suggesting a potential upside of 15.16%. Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 24.04%. Given Teva Pharmaceutical Industries' higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than argenex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
argenex
0 Sell rating(s)
4 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.92
Teva Pharmaceutical Industries
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

Summary

argenex beats Teva Pharmaceutical Industries on 11 of the 17 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 24.04%. Given Teva Pharmaceutical Industries' stronger consensus rating and higher probable upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Takeda Pharmaceutical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
Teva Pharmaceutical Industries
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, Teva Pharmaceutical Industries had 12 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 15 mentions for Teva Pharmaceutical Industries and 3 mentions for Takeda Pharmaceutical. Teva Pharmaceutical Industries' average media sentiment score of 1.20 beat Takeda Pharmaceutical's score of 0.05 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Teva Pharmaceutical Industries
11 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Teva Pharmaceutical Industries has lower revenue, but higher earnings than Takeda Pharmaceutical. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Takeda Pharmaceutical$28.32B1.76-$1.01B$0.3940.09
Teva Pharmaceutical Industries$17.35B2.23$1.41B$1.3325.32

Takeda Pharmaceutical has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Takeda Pharmaceutical's net margin of 4.31%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Takeda Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical4.31% 11.20% 5.48%
Teva Pharmaceutical Industries 9.01%43.53%8.19%

Takeda Pharmaceutical pays an annual dividend of $0.25 per share and has a dividend yield of 1.6%. Teva Pharmaceutical Industries pays an annual dividend of $1.0110 per share and has a dividend yield of 3.0%. Takeda Pharmaceutical pays out 64.1% of its earnings in the form of a dividend. Teva Pharmaceutical Industries pays out 76.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Summary

Teva Pharmaceutical Industries beats Takeda Pharmaceutical on 15 of the 18 factors compared between the two stocks.

How does Teva Pharmaceutical Industries compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Revolution Medicines' net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Revolution MedicinesN/A -83.22% -59.06%
Teva Pharmaceutical Industries 9.01%43.53%8.19%

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

Revolution Medicines currently has a consensus target price of $123.72, suggesting a potential downside of 30.56%. Teva Pharmaceutical Industries has a consensus target price of $41.78, suggesting a potential upside of 24.04%. Given Teva Pharmaceutical Industries' higher possible upside, analysts clearly believe Teva Pharmaceutical Industries is more favorable than Revolution Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Revolution Medicines
1 Sell rating(s)
1 Hold rating(s)
17 Buy rating(s)
3 Strong Buy rating(s)
3.00
Teva Pharmaceutical Industries
1 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.80

Teva Pharmaceutical Industries has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Revolution Medicines$11.58M3,271.07-$1.13B-$7.07N/A
Teva Pharmaceutical Industries$17.35B2.23$1.41B$1.3325.32

In the previous week, Teva Pharmaceutical Industries had 2 more articles in the media than Revolution Medicines. MarketBeat recorded 15 mentions for Teva Pharmaceutical Industries and 13 mentions for Revolution Medicines. Teva Pharmaceutical Industries' average media sentiment score of 1.20 beat Revolution Medicines' score of 0.74 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Revolution Medicines
3 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
11 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Teva Pharmaceutical Industries beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

Get Teva Pharmaceutical Industries News Delivered to You Automatically

Sign up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TEVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TEVA vs. The Competition

Export
MetricTeva Pharmaceutical IndustriesMED IndustryMedical SectorNYSE Exchange
Market Cap$39.35B$6.04B$6.61B$23.16B
Dividend YieldN/A0.64%2.67%4.06%
P/E Ratio25.329.1825.7631.50
Price / Sales2.2323.43558.1620.78
Price / Cash9.178.7846.3324.53
Price / Book4.904.3110.714.69
Net Income$1.41B$99.67M$3.57B$1.07B
7 Day Performance6.93%6.28%0.79%-0.15%
1 Month Performance-2.82%5.58%0.21%-0.18%
1 Year Performance102.70%127.60%30.83%23.79%

Teva Pharmaceutical Industries Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TEVA
Teva Pharmaceutical Industries
4.8415 of 5 stars		$33.68
-1.6%		$41.78
+24.0%		+98.1%$39.35B$17.35B25.3233,950
SNY
Sanofi
4.6963 of 5 stars		$41.78
-1.4%		$51.00
+22.1%		-12.6%$102.75B$49.35B11.6774,846
GSK
GSK
3.6417 of 5 stars		$50.70
+0.1%		$53.00
+4.5%		+35.3%$102.61B$43.07B13.1866,841
ARGX
argenex
4.3377 of 5 stars		$903.75
+3.0%		$1,019.50
+12.8%		+58.5%$54.58B$4.25B40.241,863
TAK
Takeda Pharmaceutical
2.561 of 5 stars		$15.46
-1.1%		N/A+4.4%$49.74B$28.32B39.6347,455

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:TEVA) was last updated on 6/26/2026 by MarketBeat.com Staff.
From Our Partners
3 Wall St. Legends Have Same Dark Prediction for June 29th
Three Wall Street legends are pointing to the same date - June 29th - as a potential turning point driven by a...
TradeSmith | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Gold Is About to Do Something It Hasn’t in 90 Years
The U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...
US Gold Bureau | Sponsoredtc pixel
SpaceX IPO “cancelled”?
SpaceX is approaching what could be a $1.6 trillion IPO - potentially the largest in history. But Louis Navell...
InvestorPlace | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
The EPA just put a kill switch on Elon’s empire
A federal EPA permit expires January 2, 2027 - and if Elon Musk's Colossus supercomputer loses power that day,...
Behind the Markets | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
BlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely, LLC | Sponsoredtc pixel